Tudor Investment Corp ET AL Buys 60,685 Shares of Bristol-Myers Squibb Company (BMY)
Tudor Investment Corp ET AL raised its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 279.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 82,386 shares of the biopharmaceutical company’s stock after buying an additional 60,685 shares during the period. Tudor Investment Corp ET AL’s holdings in Bristol-Myers Squibb were worth $4,591,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently bought and sold shares of BMY. First Trust Advisors LP grew its position in shares of Bristol-Myers Squibb by 10.7% in the second quarter. First Trust Advisors LP now owns 433,050 shares of the biopharmaceutical company’s stock valued at $24,130,000 after purchasing an additional 41,892 shares during the last quarter. Toronto Dominion Bank grew its position in shares of Bristol-Myers Squibb by 54.0% in the first quarter. Toronto Dominion Bank now owns 464,591 shares of the biopharmaceutical company’s stock valued at $25,264,000 after purchasing an additional 162,884 shares during the last quarter. Oppenheimer & Co. Inc. grew its position in shares of Bristol-Myers Squibb by 2.5% in the second quarter. Oppenheimer & Co. Inc. now owns 358,509 shares of the biopharmaceutical company’s stock valued at $19,976,000 after purchasing an additional 8,813 shares during the last quarter. Mutual of America Capital Management LLC grew its position in shares of Bristol-Myers Squibb by 1.9% in the first quarter. Mutual of America Capital Management LLC now owns 201,037 shares of the biopharmaceutical company’s stock valued at $10,932,000 after purchasing an additional 3,833 shares during the last quarter. Finally, Dividend Assets Capital LLC acquired a new stake in shares of Bristol-Myers Squibb in the second quarter valued at about $737,000. Institutional investors own 69.82% of the company’s stock.
In other news, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the transaction, the executive vice president now owns 584,373 shares in the company, valued at $37,031,717.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.77 earnings per share. equities research analysts predict that Bristol-Myers Squibb Company will post 2.99 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, February 1st. Stockholders of record on Friday, January 5th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Thursday, January 4th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.56%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s payout ratio is 61.42%.
Several equities research analysts have recently issued reports on the company. Barclays raised their price target on Bristol-Myers Squibb from $58.00 to $65.00 and gave the company an “equal weight” rating in a research report on Friday, October 13th. Jefferies Group downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 target price on the stock. in a research report on Monday, October 16th. BMO Capital Markets set a $49.00 target price on Bristol-Myers Squibb and gave the stock a “sell” rating in a research report on Thursday, October 12th. Leerink Swann lifted their target price on Bristol-Myers Squibb from $61.00 to $72.00 and gave the stock an “outperform” rating in a research report on Monday, October 23rd. Finally, Citigroup lifted their target price on Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research report on Wednesday, October 18th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $64.93.
ILLEGAL ACTIVITY WARNING: “Tudor Investment Corp ET AL Buys 60,685 Shares of Bristol-Myers Squibb Company (BMY)” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.watchlistnews.com/tudor-investment-corp-et-al-buys-60685-shares-of-bristol-myers-squibb-company-bmy/1757168.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.